Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...
MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...
The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback